At or above the 35 U/ml cutoff, CA125 demonstrated a PPV of 10.1% (95% CI 9.1–11.2), an NPV of 99.8% (95% CI 99.7–99.8), a sensitivity of 77.0% (95% CI 72.8–80.8%) and a specificity of 93.8% (95% CI 93.6–94.0) for ovarian cancer. This evidence concerns the gene MUC16 and ovarian cancer.